Abstract
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) announced today that it is awarding $1 million to biotechnology company Zeteo Tech to advance work on a noninvasive diagnostic test that can diagnose lower respiratory tract infections (LRTIs) from exhaled breath.
Key Data
-
Publication Date03 September 2025
-
Primary AuthorChris Dall
-
Sourcecidrap.umn.edu
-
LanguageEnglish
Click below to visit original source: